scholarly journals Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College—Rhode Island, 2015–2016

2017 ◽  
Vol 64 (8) ◽  
pp. 1115-1122 ◽  
Author(s):  
Heidi M. Soeters ◽  
Melissa Whaley ◽  
Nicole Alexander-Scott ◽  
Koren V. Kanadanian ◽  
Jessica R. MacNeil ◽  
...  
Keyword(s):  
Rhode Island ◽  
Meningococcal Disease ◽  
Vaccination Campaign ◽  
Disease Outbreak ◽  
Mass Vaccination ◽  
Mass Vaccination Campaign

scholarly journals Parents’ and Adolescents’ Willingness to be Vaccinated Against Serogroup B Meningococcal Disease during a Mass Vaccination in Saguenay–Lac-St-Jean (Quebec)

2015 ◽  
Vol 26 (3) ◽  
pp. 163-167 ◽  
Author(s):  
Eve Dubé ◽  
Dominique Gagnon ◽  
Denis Hamel ◽  
Sylvie Belley ◽  
Hélène Gagné ◽  
...  
Keyword(s):  
Meningococcal Disease ◽  
Endemic Area ◽  
Telephone Survey ◽  
Vaccination Campaign ◽  
Negative Attitude ◽  
Mass Vaccination ◽  
Mass Vaccination Campaign ◽  
4Cmenb Vaccine ◽  
Self Protection ◽  
To Receive

A mass vaccination campaign with the 4CMenB vaccine (Bexsero®; Novartis Pharmaceutical Canada Inc) was launched in a serogroup B endemic area in Quebec. A telephone survey was conducted to assess parental and adolescent opinions about the acceptability of the vaccine. Intent to receive the vaccine or vaccine receipt was reported by the majority of parents (93%) and adolescents (75%). Meningitis was perceived as being a dangerous disease by the majority of parents and adolescents. The majority of respondents also considered the 4CMenB vaccine to be safe and effective. The main reason for positive vaccination intention or behaviour was self-protection, while a negative attitude toward vaccination in general was the main reason mentioned by parents who did not intend to have their child vaccinated. Adolescents mainly reported lack of interest, time or information, and low perceived susceptibility and disease severity as the main reasons for not intending to be vaccinated or not being vaccinated.

Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch

Vaccine ◽  
2019 ◽  
Vol 37 (31) ◽  
pp. 4243-4245 ◽  
Author(s):  
G. Deceuninck ◽  
B. Lefebvre ◽  
R. Tsang ◽  
J.F. Betala-Belinga ◽  
G. De Serres ◽  
...  
Keyword(s):  
Meningococcal Disease ◽  
Vaccination Campaign ◽  
Mass Vaccination ◽  
Mass Vaccination Campaign

scholarly journals Mass Vaccination Campaign Following Community Outbreak of Meningococcal Disease

2002 ◽  
Vol 8 (12) ◽  
pp. 1398-1403 ◽  
Author(s):  
Gérard Krause ◽  
Carina Blackmore ◽  
Steven Wiersma ◽  
Cheryll Lesneski ◽  
Laurey Gauch ◽  
...  
Keyword(s):  
Meningococcal Disease ◽  
Vaccination Campaign ◽  
Mass Vaccination ◽  
Mass Vaccination Campaign

scholarly journals Impact of a mass vaccination campaign against a meningitis epidemic in a refugee camp

1996 ◽  
Vol 1 (3) ◽  
pp. 385-392 ◽  
Author(s):  
Edwige Haelterman ◽  
Marleen Boelaert ◽  
Carl Suetens ◽  
Lucie Blok ◽  
Myriam Henkens ◽  
...  
Keyword(s):  
Vaccination Campaign ◽  
Refugee Camp ◽  
Mass Vaccination ◽  
Mass Vaccination Campaign

scholarly journals Measles Outbreak Associated With Low Vaccine Effectiveness Among Adults in Pohnpei State, Federated States of Micronesia, 2014

2016 ◽  
Vol 3 (2) ◽  
Author(s):  
Craig M. Hales ◽  
Eliaser Johnson ◽  
Louisa Helgenberger ◽  
Mark J. Papania ◽  
Maribeth Larzelere ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Vaccination Campaign ◽  
Vaccine Effectiveness ◽  
Mass Vaccination ◽  
Cold Chain ◽  
Primary Case ◽  
Federated States Of Micronesia ◽  
Measles Outbreak ◽  
Mass Vaccination Campaign ◽  
Vaccination Campaigns

Abstract Background.  A measles outbreak in Pohnpei State, Federated States of Micronesia in 2014 affected many persons who had received ≥1 dose of measles-containing vaccine (MCV). A mass vaccination campaign targeted persons aged 6 months to 49 years, regardless of prior vaccination. Methods.  We evaluated vaccine effectiveness (VE) of MCV by comparing secondary attack rates among vaccinated and unvaccinated contacts after household exposure to measles. Results.  Among 318 contacts, VE for precampaign MCV was 23.1% (95% confidence interval [CI], −425 to 87.3) for 1 dose, 63.4% (95% CI, −103 to 90.6) for 2 doses, and 95.9% (95% CI, 45.0 to 100) for 3 doses. Vaccine effectiveness was 78.7% (95% CI, 10.1 to 97.7) for campaign doses received ≥5 days before rash onset in the primary case and 50.4% (95% CI, −52.1 to 87.9) for doses received 4 days before to 3 days after rash onset in the primary case. Vaccine effectiveness for most recent doses received before 2010 ranged from 51% to 57%, but it increased to 84% for second doses received in 2010 or later. Conclusions.  Low VE was a major source of measles susceptibility in this outbreak; potential reasons include historical cold chain inadequacies or waning of immunity. Vaccine effectiveness of campaign doses supports rapid implementation of vaccination campaigns in outbreak settings.

Sign in / Sign up

Export Citation Format

Share Document